Literature DB >> 32037484

Estradiol-Induced MMP-9 Expression via PELP1-Mediated Membrane-Initiated Signaling in ERα-Positive Breast Cancer Cells.

Yu Pan1, Xiuli Wang2, Yanzhi Zhang2, Juanjuan Qiao2, Hironobu Sasano3, Keely McNamara3, Baoshan Zhao2, Dongmei Zhang2, Yuhua Fan2, Lili Liu2, Xueling Jia2, Ming Liu4, Sihang Song5, Lin Wang6.   

Abstract

Proline-, glutamic acid-, leucine-rich protein 1 (PELP1) is a novel estrogen receptor (ER) coregulator, demonstrated distinctive characters from other ERα coregulators, and has been suggested to be involved in metastasis of several cancers. In ERα-positive breast cancer, PELP1 overexpression enhanced ruffles and filopodium-like structure stimulated by estradiol (E2) through extranuclear cell signaling transduction hereby increased cell motility. However, whether PELP1 is also involved in extracellular matrix remodeling of ERα-positive breast cancer cells is still unknown. In this study, we investigated the role of PELP1 in E2-induced MMP-9 expression and the underlined mechanism. The results demonstrated the following: E2-induced ERα-positive MCF-7 breast cancer cell MMP-9 mRNA and protein expression in a rapid response and concentration-dependent manner. Knocked down PELP1 significantly suppressed E2-induced MMP-9 expression. E2-bovine serum albumin (BSA), a large molecular membrane-impenetrable conjugate of E2, can also upregulate MMP-9 protein expression in MCF-7, and the action of E2-BSA can be abolished by PI3K inhibitor LY294002; treating MCF-7 simultaneously with PELP1-shRNA and LY294002 did not show synergetic inhibitory effect on E2-BSA-induced MMP-9 expression. Our results indicated that estrogen-induced MMP-9 expression in ER-positive breast cancer cells may be through PELP1-mediated PI3K/Akt signaling pathway.

Entities:  

Keywords:  Breast cancer; Estrogen; Matrix metalloproteinase-9; Proline-, glutamic acid–, leucine-rich protein 1

Mesh:

Substances:

Year:  2020        PMID: 32037484     DOI: 10.1007/s12672-020-00380-8

Source DB:  PubMed          Journal:  Horm Cancer        ISSN: 1868-8497            Impact factor:   3.869


  3 in total

Review 1.  Scaffolding proteins mediating membrane-initiated extra-nuclear actions of estrogen receptor.

Authors:  Viroj Boonyaratanakornkit
Journal:  Steroids       Date:  2011-02-25       Impact factor: 2.668

2.  Molecular cloning and characterization of PELP1, a novel human coregulator of estrogen receptor alpha.

Authors:  R K Vadlamudi; R A Wang; A Mazumdar; Y Kim; J Shin; A Sahin; R Kumar
Journal:  J Biol Chem       Date:  2001-07-31       Impact factor: 5.157

Review 3.  Emerging significance of ER-coregulator PELP1/MNAR in cancer.

Authors:  S Nair; R K Vadlamudi
Journal:  Histol Histopathol       Date:  2007-01       Impact factor: 2.303

  3 in total
  4 in total

1.  TAp63 regulates bone remodeling by modulating the expression of TNFRSF11B/Osteoprotegerin.

Authors:  Anna Maria Lena; Erica Foffi; Massimiliano Agostini; Mara Mancini; Margherita Annicchiarico-Petruzzelli; Daniel Aberdam; Tania Velletri; Yufang Shi; Gerry Melino; Ying Wang; Eleonora Candi
Journal:  Cell Cycle       Date:  2021-11-11       Impact factor: 4.534

2.  Role of estrogen receptor coregulators in endocrine resistant breast cancer.

Authors:  Kristin A Altwegg; Ratna K Vadlamudi
Journal:  Explor Target Antitumor Ther       Date:  2021-08-30

3.  Umbelliferone and scopoletin target tyrosine kinases on fibroblast-like synoviocytes to block NF-κB signaling to combat rheumatoid arthritis.

Authors:  Qilei Chen; Wenmin Zhou; Yueming Huang; Yuanyang Tian; Sum Yi Wong; Wing Ki Lam; Ka Yee Ying; Jianye Zhang; Hubiao Chen
Journal:  Front Pharmacol       Date:  2022-07-25       Impact factor: 5.988

Review 4.  Long non-coding RNAs affecting cell metabolism in cancer.

Authors:  Massimiliano Agostini; Mara Mancini; Eleonora Candi
Journal:  Biol Direct       Date:  2022-10-01       Impact factor: 7.173

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.